Maxim Group Analysts Give Actinium Pharmaceuticals (ATNM) a $3.00 Price Target

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) received a $3.00 target price from equities researchers at Maxim Group in a research note issued on Tuesday, March 20th. The firm currently has a “buy” rating on the biotechnology company’s stock.

ATNM has been the subject of a number of other reports. Zacks Investment Research upgraded Actinium Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a research note on Tuesday, January 16th. B. Riley set a $3.00 price objective on Actinium Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, February 16th. Five investment analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and an average price target of $3.70.

How to Become a New Pot Stock Millionaire

ATNM stock traded up $0.01 during mid-day trading on Tuesday, reaching $0.38. The company had a trading volume of 1,039,850 shares, compared to its average volume of 802,172. Actinium Pharmaceuticals has a 52 week low of $0.35 and a 52 week high of $1.61.

A hedge fund recently raised its stake in Actinium Pharmaceuticals stock. D.A. Davidson & CO. increased its position in shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) by 227.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 157,000 shares of the biotechnology company’s stock after purchasing an additional 109,000 shares during the period. D.A. Davidson & CO. owned approximately 0.20% of Actinium Pharmaceuticals worth $104,000 as of its most recent filing with the Securities and Exchange Commission.

COPYRIGHT VIOLATION WARNING: This article was first posted by Macon Daily and is owned by of Macon Daily. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://macondaily.com/2018/04/12/actinium-pharmaceuticals-atnm-given-a-3-00-price-target-by-maxim-group-analysts-updated-updated-updated.html.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a biopharmaceutical company, develops targeted payload immunotherapeutics for the treatment of advanced cancers. The company's proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively.

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply